(function(){
			var content_array=["<p><b>关于<\/b><b>PPF<\/b><\/p> \n<p>进展性肺纤维化（PPF）影响着全球多达560万人。<sup>[8]<\/sup>这是一种进展性疾病，最终会导致患者死亡，其特征是肺部出现不可逆的瘢痕，并且随着时间的推移而加重。<sup>[8]<\/sup>肺部瘢痕可能与类风湿性关节炎或系统性硬化症等基础疾病有关，也可能由吸入性物质引起。<sup>[1]<\/sup><sup>,[8]<\/sup><sup>,[9]<\/sup>在这些疾病中，肺组织的慢性瘢痕往往是导致早期死亡的主要原因。大约半数的PPF患者在确诊后五年内死亡。<sup>[2]<\/sup>平均而言，确诊延迟长达两年，而且多达一半的确诊患者未接受治疗。<sup>[13],[14]<\/sup><\/p> \n<p><b>关于那米司特<\/b><\/p> \n<p>那米司特是一款口服、选择性磷酸二酯酶4B（PDE4B）抑制剂，已在中国获批用于治疗成人IPF和PPF。该药已获得美国食品药品监督管理局（FDA）授予的优先审评资格和突破性疗法认定，并获批用于治疗IPF；目前，FDA正在优先审评该药用于治疗成人PPF。<\/p> \n<p>那米司特用于治疗IPF和PPF的上市申请也正在欧盟、英国、日本和其他国家\/地区进行注册审查，2026年预计将有更多国家\/地区获批该产品。<\/p> \n<p><b>关于勃林格殷格翰<\/b><\/p> \n<p>勃林格殷格翰是全球领先的生物制药企业，布局人用药品、动物保健两大业务领域。公司研发投入位居行业前列，致力于研究突破性疗法，解决巨大未满足的医疗需求，从而帮助改善或延长生命。自1885年成立以来，勃林格殷格翰一直是独立的家族企业，始终着眼长远发展，将可持续发展理念贯穿全价值链。公司在全球有超过5.45万名员工，服务逾130个市场，致力于打造一个更健康、更可持续、更公平的未来。更多详情，请访问：<a href=\"https:\/\/t.prnasia.com\/t\/ygetUh8w\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.boehringer-ingelheim.cn<\/a>， <a href=\"https:\/\/t.prnasia.com\/t\/tpp79iwd\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.boehringer-ingelheim.com<\/a><\/p> \n<p><b>References<\/b><\/p> \n<p>[1] Kondoh Y, Inoue Y. Progressive Pulmonary Fibrosis: Current Status in Terminology and Future Directions.&nbsp;<i><span class=\"xn-person\">Adv Ther<\/span><\/i>. 2025;42(7):2988–3001<br \/>[2] Cen Z, <i>et al.<\/i> Outcomes and predictors of&nbsp;progression in&nbsp;progressive&nbsp;pulmonary fibrosis<i>. Ann Med<\/i>. 2024;56(1):2406439.<br \/>[3] Siegel RL,&nbsp;<i>et al.<\/i> Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49.<br \/>[4] JASCAYD<sup>&reg;<\/sup> (nerandomilast). Package Insert of Nerandomilast Tablets. <span class=\"xn-location\">China<\/span>. (Last updated: <span class=\"xn-chron\">Dec 2025<\/span>)<br \/>[5] JASCAYD<sup>&reg;<\/sup> (nerandomilast). Prescribing Information. <span class=\"xn-location\">Ridgefield, CT<\/span>: Boehringer Ingelheim Pharmaceuticals, Inc; 202. (Last updated: <span class=\"xn-chron\">Oct 2025<\/span>).<br \/>[6] Ofev SmPC — Boehringer Ingelheim, 2025.<br \/>[7]&nbsp;Maher T, <i>et al. <\/i>Nerandomilast in Patients with Progressive Pulmonary Fibrosis. <i>N Engl J Med<\/i>. 2025 Jun 12;392(22):2193-2202.<br \/>[8] Cottin V, et al. The Burden of Progressive-Fibrosing Interstitial Lung Diseases. <i>Front Med<\/i> (Lausanne). 2022;9:799912.<br \/>[9] Wang J, <i>et al.<\/i> Pathogenesis and therapeutic targets in pulmonary fibrosis. MedComm. 2024;5:e744.<br \/>[10] Nasser M, Larrieu S, Boussel L, <i>et al.<\/i> Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in <span class=\"xn-location\">France<\/span> (the PROGRESS study). <i>Respir Res<\/i> 2021. 22 :162<br \/>[11] Torrisi S, <i>et al.<\/i> HRCT and histology in the evaluation of fibrotic lung&nbsp;diseases: A correlation study.&nbsp;<i>Eur&nbsp;Respir Rev<\/i>. 2017;26(145).<br \/>[12] Levra S<i> et al<\/i>. Long-term safety of antifibrotic drugs in IPF: a real-world experience.&nbsp;<i>Biomedicine<\/i>s. 2022;10(12):3229. <br \/>[13] Chaudhuri <i>et al. Respiratory Research<\/i> 2024; 25:364<br \/>[14] Wijsenbeek M<i> et al. Current Medical Research and Opinion <\/i>2019; 35 (11): 2015-2024<\/p>"];
			$("#dvExtra").html(content_array[0]);})();